Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
复制标题
DOI：
10.1093/infdis/161.6.1078
复制
发表时间：
1990-06
期刊：
影响因子：
--
通讯作者：
S. Safrin;T. Assaykeen;S. Follansbee;J. Mills
中科院分区：
文献类型：
--
作者：
S. Safrin;T. Assaykeen;S. Follansbee;J. Mills
皮肤粘膜单纯疱疹病毒（HSV）感染，对阿昔洛韦治疗耐药已被确认与获得性免疫缺陷综合征患者的频率越来越高，虽然在这种情况下的替代疗法还没有得到广泛的研究。26例连续感染人类免疫缺陷病毒的患者，接受膦甲酸治疗阿昔洛韦耐药HSV。在81%的患者中观察到临床反应; 73%的HSV病变完全上皮化。在所有11例再次培养的患者中记录了病毒脱落的停止。虽然不良反应频繁，只有3例患者（12%）的毒性需要停止治疗。在膦甲酸治疗前，14例患者接受阿糖腺苷治疗阿昔洛韦耐药HSV。在任何接受阿糖腺苷治疗的患者中，感染均未消退，4例（29%）患者因毒性而停止治疗。
Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied. Twenty-six consecutive patients are reported with human immunodeficiency virus infection, who received foscarnet therapy for acyclovir-resistant HSV. Clinical response was noted in 81% of patients; complete reepithelialization of HSV lesions occurred in 73%. Cessation of viral shedding was documented in all of the 11 patients who were recultured. Although adverse effects were frequent, in only 3 patients (12%) did toxicity necessitate discontinuation of therapy. Before foscarnet therapy, 14 patients received vidarabine for acyclovir-resistant HSV. The infection did not resolve in any of the vidarabine-treated patients, and therapy was discontinued in 4 (29%) due to toxicity.